Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Neoplasms 3Neoplasm Metastasis 2Colorectal Neoplasms 2Uterine Neoplasms 1Triple Negative Breast Neoplasms 1Recurrence 1Endometrial Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Advanced Cancer 1

Interventions

Paclitaxel 6Radiotherapy 2Pemetrexed 2Carboplatin 2Brachytherapy 2tucatinib 1seribantumab 1osimertinib 1gedatolisib 1fosaprepitant 1fluciclovine F-18 1cobimetinib 1atezolizumab 1alovudine 1Trastuzumab 1Therapeutics 1TP protocol 1Saline Solution 1Radiation 1Protons 1Palliative Care 1Nivolumab 1Letrozole 1Immunoglobulin G 1Imatinib Mesylate 1Ifosfamide 1Gemcitabine 1Fulvestrant 1FANG vaccine 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Uterine Neoplasms × gedatolisib × Clear all
NCT01420081 2019-01-08

A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer

Pfizer

Phase 2 Terminated
67 enrolled 37 charts
Gynecologic

Neoplasm Metastasis, Neoplasms, Recurrence, Uterine Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡